focus -WSS

focus

author：Wikipedia 2025-10-01 17:20:25 - browse：467

Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, as the race among pharmaceutical companies to offer weight loss medications intensifies.

The deal indicates Lilly is aiming to diversify its growing portfolio of weight loss therapies, as Versanis’ drug employs an entirely different mechanism than the existing obesity drugs that Lilly is studying. The pharma giant didn’t say how much it would pay Versanis upfront, but said that if the drug meets certain milestones, the total payment could reach $1.9 billion.

Lilly, along with other pharma companies like Novo Nordisk, has been developing products in the class of GLP-1 drugs, which mimic the glucagon-like peptide 1 hormone that helps people feel full. These drugs – including Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro – have exploded in popularity because they lead to significant weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Eating disorder hotline's move to chatbot carried cost for volunteers

WSS

GOP inquiry over gain

Medical experts exlpore how to eliminate bias in clinical algorithms

Ukrainian soldiers say they owe lives to US

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

Thousands protest in Iraq for a second day over burning of Quran in Sweden

Ukrainian soldiers say they owe lives to US

knowledge

focus

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

Synthetic human embryos? Researchers say term is overblown

ChatGPT in medicine: STAT answers readers' burning questions

UCSF medical school apologizes for unethical prisoner experiments

Trump demands the U.S. pay no more for drugs than other countries … again

UnitedHealth starts bidding war with $3.3 billion offer for Amedisys

ChatGPT in medicine: STAT answers readers' burning questions

A clever new way to fix Medicaid and graduate medical education

Supreme Court strikes down use of affirmative action

Excited delirium, Elijah McClain, and emergency physicians

knowledge

Synthetic human embryos? Researchers say term is overblown

Why do we get seasonal allergies?

MoonLake credibility takes another hit with mid

Ukrainian soldiers say they owe lives to US

Here's how to stay safe from wildfire smoke amid reduced air quality

Senate panel clears PBM, hopsital reforms

entertainment

entertainment

Wikipedia

focus